Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Protein phosphatase 2A (PP2A) is a dephosphorylating enzyme, loss of which can contribute to prostate cancer (PCa) pathogenesis. The aim of this study was to analyse the transcriptional and translational expression patterns of individual subunits of the PP2A holoenzyme during PCa progression. METHODS: Immunohistochemistry (IHC), western blot, and real-time PCR was performed on androgen-dependent (AD) and androgen-independent (AI) PCa cells, and benign and malignant prostate tissues for all the three PP2A (scaffold, regulatory, and catalytic) subunits. Mechanistic and functional studies were performed using various biochemical and cellular techniques. RESULTS: Through immunohistochemical analysis we observed significantly reduced levels of PP2A-A and -B'γ subunits (P<0.001 and P=0.0002) in PCa specimens compared with benign prostate. Contemporarily, there was no significant difference in PP2A-C subunit expression between benign and malignant tissues. Similar to the expression pattern observed in tissues, the endogenous levels of PP2A-A and B'γ subunits were abrogated from the low metastatic to high metastatic and AD to AI cell line models, without any change in the catalytic subunit expression. Furthermore, using in vitro studies we demonstrated that PP2A-Aα scaffold subunit has a role in dampening AKT, β-catenin, and FAK (focal adhesion kinase) signalling. CONCLUSION: We conclude that loss of expression of scaffold and regulatory subunits of PP2A is responsible for its altered function during PCa pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, W., Arroyo, J. D., Timmons, J. C., Possemato, R., & Hahn, W. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1103 · Cited by 159 · cited 2×
“Functional haploinsufficiency of PP2A-Aa or loss of PP2A-Aa are defective in binding with B0g, resulting in complete loss of hetrotrimeric complex formation, eventually leading to cellular transformation (Chen et al, 2005), thus supporting the tumour suppressor nature of PP2A (Mumby, 2007).”
BackgroundRetractedSerine/threonine phosphatases: mechanism through structure
Shi, Y. (2009) · Cell · doi:10.1016/j.cell.2009.10.006 · Cited by 1,488 · cited 1×
“To provide further complexity, each member of the regulatory subunit is subdivided into various isoforms like a, b, g, d, and e (Kamibayashi et al, 1994; Shi, 2009).”
BackgroundCrystal structure of a protein phosphatase 2A heterotrimeric holoenzyme
Cho, U. S., & Xu, W. (2007) · Nature · doi:10.1038/nature05351 · Cited by 459 · cited 1×
“Serine or proline phosphorylation of PR61/B0 subunit by ERK would lead to its dissociation from the catalytic or holoenzyme complex (Letourneux et al, 2006; Cho and Xu, 2007).”
BackgroundStructure of the Protein Phosphatase 2A Holoenzyme
Xu, Y., Xing, Y., Chen, Y., Chao, Y., Lin, Z., Fan, E., Yu, J. W., Strack, S., Jeffrey, P. D., & Shi, Y. (2006) · Cell · doi:10.1016/j.cell.2006.11.033 · Cited by 450 · cited 1×
“The regulation of PP2A activity mainly relies on the regulatory B subunit, which determines substrate selectivity, subcellular localisation, and regulates the catalytic activity in a wide range of biological processes (Yang et al, 2003; Yang and Phiel, 2010).”
BackgroundPP2A holoenzyme assembly: In cauda venenum (the sting is in the tail)
Janssens, V., Longin, S., & Goris, J. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.12.004 · Cited by 390
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344 · cited 3×
“In various malignancies, such as lung, breast, colon, gastric, and leukaemia, it has been shown that PP2A is downregulated and its role in transformation clearly defines PP2A as a tumour suppressor gene (Westermarck and Hahn, 2008).”
BackgroundInfluentialIdentification of specific PP2A complexes involved in human cell transformation
Chen, W., Possemato, R., Campbell, K. T., Plattner, C. A., Pallas, D. C., & Hahn, W. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00026-1 · Cited by 325 · cited 3×
“Chen et al (2004) have demonstrated that suppression of a specific regulatory subunit PP2A-B0g is sufficient for human cellular transformation by displacing PP2A-B0g from the AC dimer altering the PP2A-specific phosphatase activity in human embryonic kidney epithelial cells (Chen et al, 2004).”
BackgroundPP2A: Unveiling a Reluctant Tumor Suppressor
Mumby, M. (2007) · Cell · doi:10.1016/j.cell.2007.06.034 · Cited by 295
Calin, G. A., di Iasio, M. G., Caprini, E., Vorechovsky, I., Natali, P. G., Sozzi, G., Croce, C. M., Barbanti-Brodano, G., Russo, G., & Negrini, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203389 · Cited by 219 · cited 2×
“…cancers such as breast, lung, and colon have shown that the cancer-derived mutant form PPP2R1B (PP2A structural subunit) may have an impaired function because of its inability to form a complex with the catalytic and regulatory subunits (Calin et al, 2000; Ruediger et al, 2001; Tamaki et al, 2004).”
BackgroundIdentification of PP2A Complexes and Pathways Involved in Cell Transformation
Sablina, A. A., Hector, M., Colpaert, N., & Hahn, W. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2855 · Cited by 193
Kremmer, E., Ohst, K., Kiefer, J., Brewis, N., & Walter, G. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.3.1692 · Cited by 175
A truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation
Ito, A., Kataoka, T. R., Watanabe, M., Nishiyama, K., Mazaki, Y., Sabe, H., Kitamura, Y., & Nojima, H. (2000) · The EMBO Journal · doi:10.1093/emboj/19.4.562 · Cited by 159
Ruediger, R., Ruiz, J., & Walter, G. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05744-11 · Cited by 98 · cited 1×
“In addition, the direct evidence of PP2A as a tumour suppressor has been shown in a knock-in and knockout mouse model expressing E64D and E64G mutations (Ruediger et al, 2011).”
Background
Cited by
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 616
McClinch, K., Avelar, R. A., Callejas, D., Izadmehr, S., Wiredja, D., Perl, A., Sangodkar, J., Kastrinsky, D. B., Schlatzer, D., Cooper, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0123 · Cited by 78
Hein, A. L., Seshacharyulu, P., Rachagani, S., Sheinin, Y. M., Ouellette, M. M., Ponnusamy, M. P., Mumby, M. C., Batra, S. K., & Yan, Y. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2119 · Cited by 66
“The TMA was analyzed for PR55α expression by IHC using a PR55α specific antibody (14-27 or 100C1) at 1:100 dilution, as described previously (25).”
MethodSelf-citationConditional knockout in mice reveals the critical roles of Ppp2ca in epidermis development
Fang, C., Li, L., & Li, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050756 · Cited by 15
“PP2A was reported to negatively regulate the AKT pathway [20].”
Background
Metadata
- Authors
- Pandey, P., Seshacharyulu, P., Das, S., Rachagani, S., Ponnusamy, M. P., Yan, Y., Johansson, S. L., Datta, K., Fong Lin, M., & Batra, S. K.
- Venue
- British Journal of Cancer
- Published
- 2013-04-18
- Volume
- 108
- Issue
- 12
- Pages
- 2590-2600
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2071809116
- Cited by
- 39
- References
- 13
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.